Skip to main content
. Author manuscript; available in PMC: 2015 Jan 7.
Published in final edited form as: Lab Chip. 2013 Nov 7;14(1):147–156. doi: 10.1039/c3lc51039e

Figure 5.

Figure 5

HER2-GEDI CTC capture from metastatic breast cancer and gastric cancer patients. A. Disease-specific HER2-GEDI capture of CTCs. CTC enumeration (CTCs/ml) was performed using blood from healthy donors (median = 5) and breast or gastric cancer patients (median = 94). ** p < 0.01 B. CTC enumeration (CTCs/ml) was performed using blood from breast and gastric cancer patients BC: Breast Cancer; GC: Gastric Cancer. C. Representative images of gastric cancer CTCs captured on the HER2 GEDI chip and stained for the selected panel of molecular markers. CTCs (DAPI+, Cytokeratin+, CD45-); leukocytes (DAPI+, Cytokeratin-, CD45+). HER2 staining reflects a wide range of HER2 expression on the captured CTCs. Leukocytes are also shown for comparison. Scale bar: 5 µm.